Sample quality and validity are key factors in biobanking. Organisations are looking to reduce R&D spending and they are looking at samples, human tissue, for example as they are more reliable in clinical settings. SMi's 4th annual event in 2014 will follow on from the highly successful one in 2013.
We are very excited to present the 4th annual conference on Biobanking. This event is well established and is highly regarded in the biobanking field. The focus of this year's event will be on how biobanking can move forward in terms of strategy, regulation, ethics and sample quality. The conference will evaluate the challenges that many pharmaceutical companies are facing in terms of sample access and sample quality; the event will also examine the importance of networking and partnerships within biobanking.
This event will bring together industry leaders from big pharma companies, biotech companies, regulatory agencies and academia to discuss the latest developments in biobanking. This unique conference will present attendees with a complete view into the latest research and work being done in biobanking. The conference will comprise a number of presentations and case studies from key opinion leaders and updates on their latest projects, successes and challenges.